|
1
|
Kratze TB, Mazzitelli N, Star J, Dahut WL,
Jemal A and Siegel RL: Prostate cancer statistics, 2025. CA Cancer
J Clin. 75:485–497. 2025.
|
|
2
|
Braga R, Morais S, Pacheco-Figueiredo L,
Araujo N and Lunet N: Prostate cancer screening: Knowledge,
attitudes, and practices by medical doctors in portugal. J Cancer
Educ. Jun 19–2025.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takashima Y, Yoshii K, Tanaka M and
Tashiro K: Ubiquitin-proteasome pathway-linked gene signatures as
prognostic indicators in prostate cancer. Anticancer Res.
45:1825–1841. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Elgehama AM, Yang Q, He Z, Ruegg L, You S
and Yang W: Identification of a RIPK2-regulated gene signature as a
candidate biomarker for RIPK2 activity and prognosis in prostate
cancer. bioRxiv [Preprint]. 2025.04.30.651490. 2025.PubMed/NCBI
|
|
5
|
Mellor J, Hunter E and Akoulitchev A:
Paradigm lost. Cancers (Basel). 17:21872025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilkosz J, Sobieraj DW, Kaluzewski T,
Kaczmarek J, Szwalski J, Bednarek M, Morel A, Kasprzyk Z,
Kepczynski L, Salamunia J, et al: Personalized high-resolution
genetic diagnostics of prostate adenocarcinoma guided by
multiparametric magnetic resonance imaging: Results of a pilot
study. Int J Mol Sci. 26:56482025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X, Waldman L, Silberman Y, Wang M,
Tackey C, Hanna L, Vesprini D, Emmenegger U, Eisen A and
Smoragiewicz M: Mainstream model of genetic testing for prostate
cancer at a large tertiary cancer centre. Clin Genitourin Cancer.
22:1020522024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gonzalez-Peramato P, Alvarez-Maestro M,
Heredia-Soto V, Mendiola Sabio M, Linares E, Serrano A,
Alvarez-Ossorio JL, Lopez Alcina E, Prieto L, Vazquez Alonso F, et
al: Comparing prostatype P-score and traditional risk models for
predicting prostate cancer outcomes in Spain. Actas Urol Esp (Engl
Ed). 49:5017882025.PubMed/NCBI
|
|
9
|
Stella M, Russo GI, Leonardi R, Carco D,
Gattuso G, Falzone L, Ferrara C, Caponnetto A, Battaglia R, Libra
M, et al: Extracellular RNAs from whole urine to distinguish
prostate cancer from benign prostatic hyperplasia. Int J Mol Sci.
25:100792024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pattou M, Neuzillet Y, Ghoneim T, Bosset
PO, Herve JM, Vanalderwerelt V, Bohin D, Lugagne PM, Soorojebally Y
and Lebret T: PSA density correlates to pathology T stage and ISUP
grade: Insights from a cohort of 3568 radical prostatectomy cases.
World J Urol. 43:4452025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alahdal M, Perera RA, Moschovas MC, Patel
V and Perera RJ: Current advances of liquid biopsies in prostate
cancer: Molecular biomarkers. Mol Ther Oncolytics. 30:27–38. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Traphagen NA, Wheeler E, Li R, Lu F, Ahmed
B, Tewari AK, Balk SP, Nelson PS, Corey E, Long H, et al: Lack of
synergy between AR targeted therapies and PARP inhibitors in
homologous recombination-proficient prostate cancer. bioRxiv
[Preprint]. 2025.06.02.657429.2025.
|
|
13
|
Castellnou P, Gomez-Martinez M,
Gomez-Vallejo V, Baz Z, Lopez-Gallego F, Rondon-Lorefice I,
Zabala-Letona A, Poot AJ, Mendizabal I, Carracedo A, et al:
Unravelling the role of L- and D-alanine in prostate cancer: A
positron emission tomography study in a genetic mouse model. Nucl
Med Biol. 148-149:1090482025. View Article : Google Scholar
|
|
14
|
Coradduzza D, Sanna A, Di Lorenzo B,
Congiargiu A, Marra S, Cossu M, Tedde A, De Miglio MR, Zinellu A,
Mangoni AA, et al: Associations between plasma and urinary heavy
metal concentrations and the risk of prostate cancer. Sci Rep.
15:142742025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitura P, Paja W, Mlynarczyk G, Kowalski
R, Bar K and Depciuch J: Urine-based Raman markers for prostate
cancer diagnosis: A machine learning approach using fingerprint and
lipid spectral region. Spectrochim Acta A Mol Biomol Spectrosc.
344(Pt 1): 1266612026. View Article : Google Scholar
|
|
16
|
Sharma D, Mitra D, Bansal VK and Singh KV:
Study of the correlation between multi-parametric MRI (MP-MRI)
prostate findings and transrectal ultrasound (TRUS)-guided prostate
biopsy results in patients with raised serum PSA. Cureus.
17:e862162025.PubMed/NCBI
|
|
17
|
Huang S, Hart JC, Smith JF, Bench S, Yepes
LR, Griscom B and Clark-Langone KM: Tissue of origin
characterization of cell free DNA in seminal plasma: Implications
for new liquid biopsies. PLoS One. 20:e03177122025. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mo H, Hu C, Li P, Miao Z, Zhang H, Shen G
and Sun J: PSA proportion of index lesion: a novel index for
predicting prostate pathology outcomes in biopsy-naive patients
with PSA < 10 ng/ml and PI-RADS 3 lesions. World J Urol.
43:4442025. View Article : Google Scholar
|
|
19
|
Wang X, He Z, He X, Zeng R, He H, Zhang K
and Xu Y: High-efficiency detection of Total-PSA and Free-PSA in
whole blood by microfluidic chip integrated with electromagnetic
co-preprocessing. ACS Sens. 10:3878–3887. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arcay Ozturk A, Erkilic M, Bural GG, Aydin
F and Boz A: Physiological biodistribution on Ga68-PSMA PET/CT and
the factors effecting biodistribution. Ann Nucl Med. 38:894–903.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schulze A, Christoph F, Sachs M, Schroeder
J, Stephan C, Schostak M and Koenig F: Use of the prostate health
index and density in 3 outpatient centers to avoid unnecessary
prostate biopsies. Urol Int. 104:181–186. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Chang Y, Song L, Ren J, Yin L, Cao
W, Xu W and Ren S: Robotic prostatectomy for large-volume prostates
in prostate cancer: A retrospective analysis of 50 cases (>100
ml). BMC Cancer. 25:7012025. View Article : Google Scholar
|
|
23
|
Zheng B, Mo F, Shi X, Li W, Shen Q, Zhang
L, Liao Z, Fan C, Liu Y, Zhong J, et al: An automatic
deep-radiomics framework for prostate cancer diagnosis and
stratification in patients with serum prostate-specific antigen of
4.0-10.0 ng/mL: A multicenter retrospective study. Acad Radiol.
32:2709–2722. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiu L, Tian T, Ma Z, Sun J, Zhao Y, Yang
L, Ji Y, Yi L, Yan L, Xu C and Li D: Predictive value of the
pretreatment serum sialic acid/total protein ratio for bone
metastases in newly diagnosed prostate cancer patients: development
of a nomogram model. Gland Surg. 14:1066–1078. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rastogi S, Sato N, Lee S, Lee MJ, McKinney
Y, Lindenberg L, Mena E, Thomas A, Shrestha RL and Choyke PL:
Circulating tumor cells are detectable and independent of PSA and
PSMA-PET metrics in localized high-risk and biochemically recurrent
prostate cancer. medRxiv [Preprint]. 2025.07.09.25331014.
2025.PubMed/NCBI
|
|
26
|
Fan YP, Zhang YT, Zhang G, Ma L, Lv Y, Li
J, Luan Y, Zhang YX, Chen YT, Ren HY, et al: Proteomic profiling of
urinary large extracellular vesicles for the diagnosis of prostate
cancer. Anal Chem. 97:17368–17379. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen D, Ma Y, Yang A, Hu L, Zhou H, Xu J,
Chen S, Nie D, Feng W, Cai H, et al: Dual-Enhanced SERS satellite
immuno-nanocomplex for multiple PSA-Mediated PHI assay toward
clinical prostate cancer screening. Adv Sci (Weinh).
12:e24117472025. View Article : Google Scholar
|
|
28
|
Yao W, Wu J, Kong Y, Xu F, Zhou Y, Sun Q,
Gao Q, Cai Z, Yang C and Huang Y: Associations of systemic
immune-inflammation index with high risk for prostate cancer in
middle-aged and older US males: A population-based study. Immun
Inflamm Dis. 12:e13272024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hochma E, Firer MA and Minnes R:
Near-infrared and sono-enhanced photodynamic therapy of prostate
cancer cells using phyto-second harmonic generation nanoconjugates.
Polymers (Basel). 17:18312025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luo B, Zhou J, Zhan X, Ying B, Lan F and
Wu Y: Smartphone-based free-to-total prostate specific antigen
ratio detection system using a colorimetric reaction integrated
with proximity-induced bio-barcode and CRISPR/Cas12a assay. Small.
20:e23102122024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Serkan Y, Caner E, Serkan A, Bulent K,
Yasin V, Adem A and Omer Y: Significance of inflammation markers to
predict curative treatment for prostate cancer patients on active
surveillance. J Clin Lab Anal. 39:e700592025. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stojadinovic M, Jurisevic N, Stojadinovic
M and Jankovic S: Predictive clinical characteristics for adverse
pathological outcomes in intermediate- and high-risk prostate
cancer during biopsy. Int Urol Nephrol. 57:4077–4086. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yorioka MAW, Murta CB, Leite KRM, Cardili
L, de Mello ES, de Carvalho Fazoli AJ, Cordeiro MD, Coelho RF,
Viana PCC, Kohama CSN, et al: ERG and PTEN role on active
surveillance for low-risk prostate cancer in the multiparametric
MRI Era. Prostate. 85:364–373. 2025. View Article : Google Scholar
|
|
34
|
Weng Y and Ji B: Serum levels of prostate
specific antigen, free PSA, (-2)proPSA, fPSA/tPSA ratio, prostate
health index, and glycosylation patterns of free PSA in patients
with benign prostatic hyperplasia pharmacotherapy: Limitations and
future directions. Prostate. 85:1248–1249. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Encarnacion Navarro JA, Morillo Macias V,
Borras Calbo M, De la Fuente Munoz I, Lozano Martinez A, Garcia
Martinez V, Fernandez Fornos L, Guijarro Roche M, Amr Rey O and
Garcia Gomez R: Multicenter real-world study: 432 patients with
apalutamide in metastatic hormone-sensitive prostate cancer. Curr
Oncol. 32:1192025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gjelsvik YM, Myklebust TA, Fosså SD, Haug
ES, Kvåle R, Ursin G and Johannesen TB: A nationwide, longitudinal
collection of patient-reported outcomes from prostate cancer
patients and controls. Qual Life Res. 34:2689–2700. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zeng Y, Liao H, Jiang G, Wu G and Zhong J:
Diagnostic value of 18F-prostate-specific membrane antigen-1007
PET/MRI versus 18F-prostate-specific membrane antigen-1007
PET/computed tomography for biochemical recurrence of prostate
cancer after radical prostatectomy. Nucl Med Commun. 46:1052–1060.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Williams N, Remmers S, Jay A, Santoro K
and O'Callaghan M: External validation of MRI-based prostate cancer
risk calculators in an Australian cohort. ANZ J Surg. 95:1906–1911.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Van der Eecken H, De Cock D, Roussel E,
Giesen A, Vansevenant B, Goeman L, Quackels T and Joniau S:
Nutritional supplement with fermented soy in patients under active
surveillance for low-risk or intermediate-risk prostate cancer:
Results from the PRAEMUNE trial. Cancers (Basel). 16:36342024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo P, A G, Chen T, Guo Y, Tang Y, Pan J,
Wang B, Gong R, Chen G and Huang S: A hematological and
inflammatory marker-based model for prostate carcinoma diagnosis.
Am J Cancer Res. 15:2551–2563. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cirulli GO, Davis M, Stephens A, Chiarelli
G, Finati M, Chase M, Tinsley S, Arora S, Sood A, Lughezzani G, et
al: Midlife baseline prostate-specific antigen, velocity, and
doubling time association with lethal prostate cancer and
mortality. Cancer. 131:e355632025. View Article : Google Scholar
|
|
42
|
Kobayashi M, Kijima T, Yashi M and Kamai
T: Prostate-specific antigen kinetics contributes to decision
making for biopsy referral: the predictive implication for PSA
retest in patients with elevated PSA levels. Prostate Int.
11:27–33. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Javaeed A, Ghauri SK, Ibrahim A and Doheim
MF: Prostate-specific antigen velocity in diagnosis and prognosis
of prostate cancer - a systematic review. Oncol Rev. 14:4492020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ono K, Hiyoshi Y, Ono A, Ouchi M, Kosumi
K, Eto K, Ida S, Iwatsuki M, Baba Y, Miyamoto Y, et al: Locally
advanced rectal cancer in a young adult affected with dyskeratosis
congenita (Zinsser-Cole-Engman syndrome): A case report. Surg Case
Rep. 10:2062024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dai F, He Y, Duan J, Lin K, Lv Q, Zhao Z,
Zou Y, Jiang J, Zheng Z and Qiu X: Global trends in the use of
artificial intelligence for urological tumor histopathology: A
20-year bibliometric analysis. Digit Health.
11:205520762513488342025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Aktas S, Yucetas U, Yucetas E, Ates HA,
Gene C and Erkan E: The efficacy of prostate health index (PHI) in
predicting pathological progression in low-risk localized prostate
cancer cases under active surveillance protocol. World J Urol.
43:4312025. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Assam KD, Pierce JM, Galloway LA and
Tosoian JJ: Blood- and urine-based biomarkers for the detection of
clinically significant prostate cancer: A contemporary review. Curr
Opin Urol. 35:590–596. 2025. View Article : Google Scholar
|
|
48
|
Gupta VK, Cortese BD and Talwar R:
Cost-effectiveness of serum, urine, and tissue-based prostate
cancer biomarkers. Curr Opin Urol. 35:412–417. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jeon SS, Song W, Kang M, Sung HH, Jeon HG,
Jeong BC, Seo SI and Chung JH: Diagnostic value of prostate health
index in patients with no index lesion on mpMRI or negative
previous combined biopsy. Investig Clin Urol. 66:124–129. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jirasko M, Vitak R, Pecen L, Pinkeova A,
Tkac J, Bertok T, Bergman N and Kucera R: Serum levels of prostate
specific antigen, free PSA, (-2)proPSA, fPSA/tPSA ratio, prostate
health index, and glycosylation patterns of free PSA in patients
with benign prostatic hyperplasia pharmacotherapy. Prostate.
85:65–72. 2025. View Article : Google Scholar
|
|
51
|
Vakili S, Beheshti I, Barzegar Behrooz A,
Los MJ, Vitorino R and Ghavami S: Transforming prostate cancer
care: Innovations in diagnosis, treatment, and future directions.
Int J Mol Sci. 26:53862025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Britton CJ, Andrews JR, Arafa A, Kim Y,
Latuche LR, Schulte PJ, Joshi VB, Ahmed ME, Jeffrey Karnes R and
Lucien F: Prostate extracellular vesicles and prognostic biomarkers
of clinically significant prostate cancer: A prospective
single-institution pilot study. Prostate. 85:594–602. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lee IT, Hou CM, Vo TTT, Hong JH, Huang CY,
Wang YL, Chen YL and Chiang CH: Optimizing prostate cancer care:
Clinical utility of the prostate health index. Prostate.
85:1357–1368. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chung Y and Hong SK: Evaluating prostate
cancer diagnostic methods: The role and relevance of digital rectal
examination in modern era. Investig Clin Urol. 66:181–187. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fasulo V, Chiarelli G, Garofano G,
Ripamonti CB, Barile M, Bianchi P, Morenghi E, Benetti A, Aljoulani
M and Finocchiaro A: Impact of prostate cancer screening in
European ancestry un-affected men with germline DNA repair
pathogenic variants. BJUI Compass. 6:e4242025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chang CH, Yu PH, Hsieh PF, Hong JH, Chiang
CH, Cheng HM, Wu HC, Huang CY and Lin TP: Prostate health index
density aids the diagnosis of prostate cancer detected using
magnetic resonance imaging targeted prostate biopsy in Taiwanese
multicenter study. J Chin Med Assoc. 87:678–685. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stuardo-Parada A, Lopez-Munoz R,
Villarroel-Espindola F, Figueroa CD and Ehrenfeld P: Minireview:
Functional roles of tissue kallikrein, kinins, and
kallikrein-related peptidases in lung cancer. Med Oncol.
40:2242023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kelam N, Ogorevc M, Gotovac I, Kuzmic
Prusac I, Vukojevic K, Saraga-Babic M and Mardesic S: Analysis of
kallikrein 6, Acetyl-α-tubulin, and aquaporin 1 and 2 expression
patterns during normal human nephrogenesis and in congenital
anomalies of the kidney and urinary tract (CAKUT). Genes (Basel).
16:4992025. View Article : Google Scholar
|
|
59
|
Sasiadek L, Bielecka E, Falkowski K,
Kulczycka M, Bereta G, Maksylewicz A, Zubrzycka N, Dobosz E, Koziel
J, Drukala J, et al: Human tissue kallikrein 14 induces the
expression of IL-6, IL-8, and CXCL1 in skin fibroblasts through
protease-activated receptor 1 signaling. FEBS J. 292(21):
5659–5675. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Giuffre M, Lista AD, Paulson N and Masuoka
L: A phase 1C, open label, single ascending dose study to evaluate
the safety, tolerability, and pharmacokinetics of DM199
administered intravenously with a polyvinyl chloride bag in adult
healthy subjects and adults recently taking angiotensin-converting
enzyme inhibitors. Clin Pharmacol Drug Dev. 14:452–460. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Singh SP, Dhanasekara CS, Melkus MW, Bose
C, Khan SY, Sardela de Miranda F, Mahecha MF, Gukhool PJ, Tonk SS,
Jun SR, et al: Relevance of cellular homeostasis-related gene
expression signatures in distinct molecular subtypes of breast
cancer. Biomedicines. 13:10582025. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kumar N, Kole L and Singh AK: Precision
assay for detection and quantification of anti-prostate specific
antigen antibodies using indirect ELISA. Infect Disord Drug
Targets. May 15–2025.Epub ahead of print. View Article : Google Scholar
|
|
63
|
Boumali R, David E, Chaaya N, Lucas M, Ait
Amiri S, Lefort V, Nina-Diogo A, Salmain M, Petropoulos I, Corce V,
et al: Deferasirox derivatives as inhibitors of kallikrein-related
peptidases associated to neurodegenerative diseases. ChemMedChem.
20:e2025001872025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Koistinen H, Kovanen RM, Hollenberg MD,
Dufour A, Radisky ES, Stenman UH, Batra J, Clements J, Hooper JD,
Diamandis E, et al: The roles of proteases in prostate cancer.
IUBMB Life. 75:493–513. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Angel MR, Loeffler D, Charifa A, Sinit RB,
Amery T, Cengiz B, Beer TM and Thomas GV: TMPRSS2 expression in
lung tissue of prostatic adenocarcinoma patients: A pathologic
perspective on androgen deprivation therapy. medRxiv [Preprint].
2025.05.03.25326931. 2025.PubMed/NCBI
|
|
66
|
Srinivasan S, Kryza T, Batra J and
Clements J: Remodelling of the tumour microenvironment by the
kallikrein-related peptidases. Nat Rev Cancer. 22:223–238. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Stein MN, Vinceneux A, Robbrecht D, Doger
B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville
JL, et al: Real-world effectiveness of darolutamide in metastatic
castration-resistant prostate cancer. J Clin Oncol. 43:2515–2526.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhao J, Sun Y, Ren L, Huang S and Zhang J:
Antagonism of androgen receptor signaling by aloe-emodin. Food Chem
Toxicol. 181:1140922023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Boyukozer FB, Tanoglu EG, Ozen M, Ittmann
M and Aslan ES: Kallikrein gene family as biomarkers for recurrent
prostate cancer. Croat Med J. 61:450–456. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wenta T, Nastaly P, Lipinska B and
Manninen A: Remodeling of the extracellular matrix by serine
proteases as a prerequisite for cancer initiation and progression.
Matrix Biol. 134:197–219. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Matin F, Jeet V, Srinivasan S, Cristino
AS, Panchadsaram J, Clements JA and Batra J; Australian Prostate
Cancer BioResource: MicroRNA-3162-5p-mediated crosstalk between
kallikrein family members including prostate-specific antigen in
prostate cancer. Clin Chem. 65:771–780. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Nakayama H, Sekine Y, Oka D, Miyazawa Y,
Arai S, Koike H, Matsui H, Shibata Y and Suzuki K: Combination
therapy with novel androgen receptor antagonists and statin for
castration-resistant prostate cancer. Prostate. 82:314–322. 2022.
View Article : Google Scholar
|
|
73
|
Karan D, Dubey S, Gunewardena S, Iczkowski
KA, Singh M, Liu P, Poletti A, Choo YM, Chen HZ and Hamann MT:
Manzamine A reduces androgen receptor transcription and synthesis
by blocking E2F8-DNA interactions and effectively inhibits prostate
tumor growth in mice. Mol Oncol. 18:1966–1979. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Nordstrand A, Bovinder Ylitalo E, Thysell
E, Jernberg E, Crnalic S, Widmark A, Bergh A, Lerner UH and
Wikstrom P: Bone cell activity in clinical prostate cancer bone
metastasis and its inverse relation to tumor cell androgen receptor
activity. Int J Mol Sci. 19:12232018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhang J and Chadha JS: Developmental
therapeutics in metastatic prostate cancer: New targets and new
strategies. Cancers (Basel). 16:30982024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Isaacs JT, Brennen WN, Christensen SB and
Denmeade SR: Mipsagargin: The beginning-not the end-of thapsigargin
prodrug-based cancer therapeutics. Molecules. 26:74692021.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ma Z, Shi B, Wei Z, Guo W, Hu L, Li Y, Wu
X, Gong S, Wu D and Wu C: Abstract 3520: EM1031, a novel KLK2 x CD3
bispecific T-cell engager with highly effective efficacy in
preclinical models. Cancer Res. 85(8_Supplement_l): S35202025.
View Article : Google Scholar
|
|
78
|
Shen F, Smith R, McDevitt T, Menard K,
Tian S, Chu G, Chaudhary R, McCann J, Oyer H, Wang SC, et al: Human
kallikrein 2: A novel lineage-specific surface target in prostate
cancer. Clin Cancer Res. 31:4543–4556. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Vietri MT, Della Pepa C, Caliendo G,
Mignano A, Albanese L, Zitiello M, Stilo M and Molinari AM:
Expanding the genomic landscape of HBOC and cancer risk among
mutation carriers. Int J Mol Sci. 26:59282025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Nyberg T, Frost D, Barrowdale D, Evans DG,
Bancroft E, Adlard J, Ahmed M, Barwell J, Brady AF, Brewer C, et
al: Prostate cancer risks for male BRCA1 and BRCA2 mutation
carriers: A prospective cohort study. Eur Urol. 77:24–35. 2020.
View Article : Google Scholar :
|
|
81
|
Yatrano S, Pepe P, Pepe L, Vella N, Alario
C, Chiaranda A, Taranto C, Scillieri R, Mauceri C and Fraggetta F:
BRCA mutations and prostate cancer: should urologist improve daily
clinical practice? Arch Ital Urol Androl. 97:136352025.
|
|
82
|
Fizazi K, Azad AA, Matsubara N, Carles J,
Fay AP, De Giorgi U, Young Joung J, Fong PCC, Voog E, Jones RJ, et
al: Talazoparib plus enzalutamide in men with HRR-deficient
metastatic castration-resistant prostate cancer: Final overall
survival results from the randomised, placebo-controlled, phase 3
TALAPRO-2 trial. Lancet. 406:461–474. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Amini AE, Hunter AE, Almashad A, Feng AJ,
Patel ND, O'Dea MR, McCormick SR, Rodgers LH and Salari K: Magnetic
resonance imaging-based prostate cancer screening in carriers of
pathogenic germline mutations: Interim results from the initial
screening round of the prostate cancer genetic risk evaluation and
screening study. Eur Urol Oncol. 7:1358–1366. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li X and Mao J: Research progress on the
role of lipoxygenase and its inhibitors in prostate cancer. Future
Oncol. 20:3549–3568. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Santos-Pereira M, Pereira SC, Matos B,
Fardilha M, Oliveira PF and Alves MG: Increased susceptibility to
prostate cancer biomarkers in the offspring of male mouse
progenitors with lifelong or early life exposure to high-fat diet.
Eur J Nutr. 64:2122025. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Biyikoglu M, Tanriverdi R, Bozlu M, Send
S, Fidanci SB, Tamer L and Akbay E: Evaluation of homeobox protein
B13 (HOXB13) gene G84E mutation in patients with prostate cancer.
World J Urol. 42:4762024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Sulaiman KM and Hama Salih RM: Study of
HOXB13 gene variants in prostate cancer patients. Cureus.
16:e725132024.PubMed/NCBI
|
|
88
|
Barashi NS, Li T, Angappulige DH, Zhang B,
O'Gorman H, Nottingham CU, Shetty AS, Ippolito JE, Andriole GL,
Mahajan NP, et al: Symptomatic benign prostatic hyperplasia with
suppressed epigenetic regulator HOXB13 shows a lower incidence of
prostate cancer development. Cancers (Basel). 16:2132024.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
de Angelis M, Siech C, Jannello LMI, Di
Bello F, Penaranda NR, Scilipoti P, Goyal JA, Tian Z, Longo N, de
Cobelli O, et al: Does race/ethnicity affect secondary bladder and
rectal cancer rates after prostate cancer radiation? Results from a
population-based study. J Racial Ethn Health Disparities. Jul
11–2025.Epub ahead of print. View Article : Google Scholar
|
|
90
|
Wei J, Shi Z, Na R, Wang CH, Resurreccion
WK, Zheng SL, Hulick PJ, Cooney KA, Helfand BT, Isaacs WB and Xu J:
Germline HOXB13 G84E mutation carriers and risk to twenty common
types of cancer: Results from the UK Biobank. Br J Cancer.
123:1356–1359. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Chartier J, Chansavang A, Jouinot A,
Hamzaoui N, Srikaran A, Moliere D, Huillard O, Thibault C, Tiako M,
Sibony M, et al: Predisposition to prostate cancer and clinical
implications in a real-life cohort. Eur J Hum Genet. 33:1163–1172.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Fraser M, Livingstone J, Wrana JL, Finelli
A, He HH, van der Kwast T, Zlotta AR, Bristow RG and Boutros PC:
Somatic driver mutation prevalence in 1844 prostate cancers
identifies ZNRF3 loss as a predictor of metastatic relapse. Nat
Commun. 12:62482021. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Poon DM, Yuan J, Wong OL, Yang B, Chiu ST,
Cheung KY, Chiu G and Yu SK: Stereotactic total ablative
radiotherapy with MR-LINAC for synchronous oligometastatic prostate
cancer. Front Oncol. 15:16076102025. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Garcia de Herreros M, Jimenez N, Padrosa
J, Aversa C, Ferrer-Mileo L, Garcia-Esteve S, Rodriguez-Carunchio
L, Trias I, Fernandez-Manas L, Marin-Aguilera M, et al: Clinical
and transcriptomic characterization of metastatic hormone-sensitive
prostate cancer patients with low PTEN expression. Int J Mol Sci.
26:62442025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Einspieler H, Ofner H, Ozenil M,
Spielvogel CP, Langrate IK, Hassler MR, Nics L, Bamminger K,
Baltzer PAT, Shariat SF, et al: Does PARP1 up-regulation correlate
with PSMA expression in patients with metastatic
castration-resistant prostate cancer studied with ((18)F)PARPi and
((68)Ga) PSMA PET/CT? Eur J Nucl Med Mol Imaging. July 19–2025.Epub
ahead of print. View Article : Google Scholar
|
|
96
|
Handa N, Li EV, Michael J, Proudfoot JA,
Weiner AB, Alam R, Alshalalfa M, Hao Y, Hakansson A, Zhao X, et al:
Prevalence of potential candidates for targeted therapies according
to treatment-related transcriptomic signatures among 140 548
patients with nonmetastatic prostate cancer. Eur Urol Oncol.
8:1050–1058. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yin L, Yang F, Wang W, Zhang L, Cao Z, Shi
H, Pan K, Wu L, Xiao H and Xing N: PSMA-Targeted nanoparticles with
PI3K/mTOR dual inhibitor downregulate P-Glycoprotein and inactivate
myeloid-derived suppressor cells for enhanced chemotherapy and
immunotherapy in prostate cancer. Adv Mater. 37:e24153222025.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Miyachi S, Sasaki T, Kato M, Higashi S,
Masui S, Nishikawa K, Fujiwara T, Kitajima T, Hashizume Y, Uchida
K, et al: Comprehensive genomic profiling tests for Japanese
patients with metastatic castration-resistant prostate cancer: A
single-institution experience. Hinyokika Kiyo. 71:171–179. 2025.In
Japanese. PubMed/NCBI
|
|
99
|
Giantini-Larsen A, Ramos AD, Martin D,
Panageas KS, Kostrzewa CE, Abou-Mrad Z, Schmitt A, Bromberg JF,
Safonov A, Rudin CM, et al: Integration of next generation
sequencing data to inform survival prediction of patients with
spine metastasis. Cancers (Basel). 17:22182025. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kldiashvili E, Abiatari I, Kekelia E,
Iordanishvili S, Metreveli T and Dumbadze E: SOX2, PIWI proteins,
and MALAT1 - plasma-based emerging biomarkers for cancer detection
and monitoring. PLoS One. 20:e03285572025. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Yazaki S, Pei X, Powell S, Khan A, Setton
J and Riaz N: AlphaMissense for identifying pathogenic missense
mutations in DNA damage repair genes in cancer. JCO Precis Oncol.
9:e24009082025. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hommerding M, Hommerding O, Bernhardt M,
Kreft T, Sanders C, Tischler V, Basitta P, Pelusi N, Wulf AL,
Ohlmann CH, et al: Real-world data on the prevalence of BRCA 1/2
and HRR gene mutations in patients with primary and metastatic
castration resistant prostate cancer. World J Urol. 42:4912024.
View Article : Google Scholar
|
|
103
|
Kwon A and Joung JY: Precision targeting
in metastatic prostate cancer: molecular insights to therapeutic
frontiers. Biomolecules. 15:6252025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Naisam S, Mohan A, Sivakumar GS,
Gopalakrishnan S and Sreekumar N: Discovering potential therapeutic
agents for lupus nephritis: Insights from in silico research.
Medinformatics. 2:226–240. 2025.
|
|
105
|
Norgaard M, Rusan M, Kondrup K, Sorensen
EMG, Weiss S, Bjerre MT, Fredsoe J, Vang S, Jensen JB, De Laere B,
et al: Deep targeted sequencing of circulating tumor DNA to inform
treatment in patients with metastatic castration-resistant prostate
cancer. J Exp Clin Cancer Res. 44:1202025. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dhabhai B, Dhakar R, Ranga V, Surolia P,
Menon AM, Sharma NK, Dakal TC and Lohar D: Integrated
bioinformatics approach showed linagliptin as potential drug for
prevention of cardiac arrest and cancer. Medinformatics. 1:131–141.
2023. View Article : Google Scholar
|
|
107
|
Yoon CE, Kang S, Rhew SA, Kwon HJ, Shin D,
Moon HW, Kim MY and Lee JY: Genetic alterations of prostate cancer:
In localized and metastatic prostate cancer. BMC Urol. 25:1662025.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wierbilowicz K, Yang CS, Almaghasilah A,
Wesolowski PA, Pracht P, Dworak NM, Masur J, Wijngaarden S,
Filippov DV, Wales DJ, et al: Parp7 generates an ADP-ribosyl degron
that controls negative feedback of androgen signaling. EMBO J.
44:4720–4744. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Fragkoulis C, Glykas I, Tzelves L,
Stamatakos PV, Papadopoulos G, Stathouros G, Dellis A, Ntoumas K,
Kostopoulou A, Deliveliotis C and Papatsoris A: Clinical impact of
ERG and PTEN status in prostate cancer patients underwent radical
prostatectomy. Arch Ital Urol Androl. 94:390–395. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Lorenzoni M, De Felice D, Beccaceci G, Di
Donato G, Foletto V, Genovesi S, Bertossi A, Cambuli F, Lorenzin F,
Savino A, et al: ETS-related gene (ERG) undermines genome stability
in mouse prostate progenitors via Gsk3β dependent Nkx3.1
degradation. Cancer Lett. 534:2156122022. View Article : Google Scholar
|
|
111
|
Ionescu CA, Cozaru GC, Aschie M, Leopa N,
Cimpineanu B, Voinea F, Matei E, Mitroi A, Deacu M, Iorga I and
Pundiche M: Toward personalized surgery in advanced prostate
cancer: Stratification by PTEN, AR-V7, TP53, TMPRSS2-ERG, and ERBB2
genetic alterations. Chirurgia (Bucur). 120:265–274. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Check MH, Ernst SE and Sfanos KS: Use of
droplet digital PCR for consistent detection of TMPRSS2:ERG gene
fusion transcripts initiated in vitro. Prostate. 85:1282–1289.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Raspin K, O'Malley DE, Marthick JR,
Donovan S, Malley RC, Banks A, Redwig F, Skala M, Dickinson JL and
FitzGerald LM: Analysis of a large prostate cancer family
identifies novel and recurrent gene fusion events providing
evidence for inherited predisposition. Prostate. 82:540–550. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Xie J, Xiang J, Shen Y and Shao S:
Mechanistic insights into the tools for intracellular protein
delivery. Chem Bio Eng. 2:132–155. 2024. View Article : Google Scholar
|
|
115
|
Dematteis A, Miszczyk M, Cormio A,
Matsukawa A, Gontero P and Shariat SF: The role of radiotherapy in
pelvic nodal recurrence following definitive treatment for prostate
cancer. Curr Opin Urol. 35:574–582. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Feng EM, Vo-Phamhi J, Subramanian AN, Dias
M, Foye A, Vinson J, Hong JC, Freedland SJ, Alumkal JJ, Beltran H,
et al: Racial variation in the advanced prostate cancer genome.
Prostate Cancer Prostatic Dis. 28:902–907. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hadjimichael AC, Foukas AF, Savvidou OD,
Mavrogenis AF, Psyrri AK and Papagelopoulos PJ: The anti-neoplastic
effect of doxycycline in osteosarcoma as a metalloproteinase (MMP)
inhibitor: A systematic review. Clin Sarcoma Res. 10:72020.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Saad F, Armstrong AJ, Shore N, George DJ,
Oya M, Sugimoto M, McKay RR, Hussain M and Clarke NW: Olaparib
monotherapy or in combination with abiraterone for the treatment of
patients with metastatic castration-resistant prostate cancer
(mCRPC) and a BRCA mutation. Target Oncol. 20:445–466. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
McGrath CB, Shreves AH, Shanahan MR, Guard
HE, Nhliziyo MV, Pernar CH, Penney KL, Lotan TL, Fiorentino M,
Mucci LA and Stopsack KH: Etiology of prostate cancer with the
TMPRSS2:ERG fusion: A systematic review of risk factors. Int J
Cancer. 156:1898–1908. 2025. View Article : Google Scholar :
|
|
120
|
Zhang H, Kong L, Li J, Liu Z, Zhao Y, Lv
X, Wu L, Chai L, You H, Jin J, et al: SPOP mutations increase PARP
inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer.
JCI Insight. 10:e1868712025. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Ding T, Li X, Zhang L, Wei Z, Xiong C,
Wang H, Hao X and Zeng X: Comparison of androgen receptor mutation
detection between plasma extracellular vesicle DNA and cell-free
DNA and its relationship to prostate cancer prognosis. Ann Med.
56:24267702024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Bugoye FC, Torrorey-Sawe R, Biegon R,
Dharsee N, Mafumiko F, Kibona H, Aboud S, Patel K and Mining S:
Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and
tumour molecular subtypes in prostate cancer management. Front
Oncol. 15:15212042025. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Urabe F and Takemura K: Evaluating the
genetic landscape of prostate cancer: New insights from BRCA1/2,
ATM and CDK12 mutations. BMJ Oncol. 4:e0007172025. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Sekar A, Chatterjee R, Selvadurai BR, Pal
LR, Verma A, Nataraj NB, Garcia DD, Giri S, Genna A, Karatekin F,
et al: TMPRSS2-ERG confers resistance to antiandrogens: Mechanism
and therapeutic implications. bioRxiv [Preprint].
2025.01.17.633582. 2025.
|
|
125
|
Qi L, Li X, Liu Z, Zhang P and Liu L: A
depth-wise separable residual neural network for PCDH8 status
prediction in thyroid cancer pathological images. Intell Oncol.
1:290–298. 2025. View Article : Google Scholar
|
|
126
|
Cheng B, Luo T, Wu Y, Hu J, Yang C, Wu J,
Luo Y, Shangguan W, Li W, Yang L, et al: Urinary exosomal
FAM153C-RPL19 chimeric RNA as a diagnostic and prognostic biomarker
for prostate cancer in Chinese patients. Cancer Lett.
631:2179382025. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Mugoni V, Ciani Y, Nardella C and
Demichelis F: Circulating RNAs in prostate cancer patients. Cancer
Lett. 524:57–69. 2022. View Article : Google Scholar
|
|
128
|
Zvirble M, Vaicekauskaite I, Survila Z,
Bosas P, Dobrovolskiene N, Mlynska A, Sabaliauskaite R and
Pasukoniene V: Liquid-based diagnostic panels for prostate cancer:
The synergistic role of soluble PD-L1, PD-1, and mRNA biomarkers.
Int J Mol Sci. 26:7042025. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Crocetto F, Musone M, Chianese S, Conforti
P, Digitale Selvaggio G, Caputo VF, Falabella R, Del Giudice F,
Giulioni C, Cafarelli A, et al: Blood and urine-based biomarkers in
prostate cancer: Current advances, clinical applications, and
future directions. J Liq Biopsy. 9:1003052025. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Cengiz T, Yurtbay A, Muslu O, Aydin Simsek
S, Ozbalci AB, Coskun HS, Baris YS and Dabak N: Evaluation of the
diagnostic accuracy of percutaneous core needle biopsy in bone and
soft tissue tumors. Acta Chir Orthop Traumatol Cech. 91:376–384.
2024. View Article : Google Scholar
|
|
131
|
Aferin U, Bahtiyar N, Onaran I and Ozkara
H: Are elevated mitochondrial DNA fragments in prostatic
inflammation a potential biomarker for prostate cancer? Arch Ital
Urol Androl. 95:116102023.PubMed/NCBI
|
|
132
|
Valentini V, Santi R, Silvestri V, Saieva
C, Roviello G, Amorosi A, Comperat E, Ottini L and Nesi G: CD44
methylation levels in androgen-deprived prostate cancer: A putative
epigenetic modulator of tumor progression. Int J Mol Sci.
26:25162025. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Su XA, Stopsack KH, Schmidt DR, Ma D, Li
Z, Scheet PA, Penney KL, Lotan TL, Abida W, DeArment EG, et al:
RAD21 promotes oncogenesis and lethal progression of prostate
cancer. Proc Natl Acad Sci USA. 121:e24055431212024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Montoya Perez I, Jambor I, Pahikkala T,
Airola A, Merisaari H, Saunavaara J, Alinezhad S, Vaananen RM,
Tallgren T, Verho J, et al: Prostate cancer risk stratification in
men with a clinical suspicion of prostate cancer using a unique
biparametric mri and expression of 11 genes in apparently benign
tissue: Evaluation using machine-learning techniques. J Magn Reson
Imaging. 51:1540–1553. 2020. View Article : Google Scholar
|
|
135
|
Gan L, Li W, Chen Q, Cheng L, Zhang F,
Zhong H, Lu Y, Zheng L and Qian B: MicroRNA-145 in urologic tumors:
Biological roles, regulatory networks, and clinical translation.
Front Pharmacol. 16:16096462025. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Rafiq A and Kanavarioti A: The potential
and limitations of the MinION/Yenos Platform for miRNA-Enabled
early cancer detection. Int J Mol Sci. 26:38222025. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Davey M, Benzina S, Savoie M, Breault G,
Ghosh A and Ouellette RG: Affinity vesicles captured urinary
extracellular provide mRNA and miRNA biomarkers for improved
accuracy of prostate cancer detection: A pilot study. Int J Mol
Sci. 21:83302020. View Article : Google Scholar
|
|
138
|
Fuso GA, Bianciardi G, Mei R, Brusa I,
Emiliani S, Fortunati E and Nanni C: Radiotracing the future:
Non-FDG radiotracers nuclear medicine. Semin Nucl Med. 55:648–663.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Cicatiello AG, Musone M, Imperatore S,
Giulioni C, La Rocca R, Cafarelli A, Del Giudice F, Dentice M and
Crocetto F: Circulating miRNAs in genitourinary cancer: Pioneering
advances in early detection and diagnosis. J Liq Biopsy.
8:1002962025. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Tong G, Jing X, Yang Y, Wang X, Lu J, Hu
J, Wang Y, Jumuddin FA, Zhang W and Lv Y: Screening and validation
of key genes involved in castration-resistant prostate cancer based
on transcriptomics sequencing. Sci Rep. 15:256482025. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Muniz M, Childs DS, Andrews J, Mahmoud AM,
Park S, Sartor O, Kase AM, Riaz IB, Stish BJ, Chaudhuri AA, et al:
Deferral of systemic therapy in patients with oligorecurrent
prostate cancer treated with metastasis-directed radiotherapy. Ann
Transl Med. 13:292025. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kwan EM, Ng SWS, Tolmeijer SH, Emmett L,
Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V,
et al: Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate
cancer: Circulating tumor DNA analysis of the randomized phase 2
TheraP trial. Nat Med. 31:2722–2736. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Shiota M, Matsubara N, Kato T, Eto M,
Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, et
al: Prediction of undetectable circulating tumor DNA by
comprehensive genomic profiling assay in metastatic prostate
cancer: The SCRUM-Japan MONSTAR SCREEN project. World J Urol.
42:5262024. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Peng N, Chen D, Yang M, Zeng C and Li W:
PARP inhibitors for HRR-deficient metastatic castration-resistant
prostate cancer: Mechanisms and clinical strategies. Eur J Pharm
Sci. 212:1071932025. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Liang A, Gulati S, Huang Q, Dowst H, Lim
A, Zarrin-Khameh N, Godoy G, Noor AB, Castro P, Scheurer ME, et al:
Real-world effectiveness of darolutamide in metastatic
castration-resistant prostate cancer. Endocr Relat Cancer.
32:e2401882025. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Sweeney CJ, Petry R, Xu C, Childress M, He
J, Fabrizio D, Gjoerup O, Morley S, Catlett T, Assaf ZJ, et al:
Circulating Tumor DNA assessment for treatment monitoring adds
value to PSA in metastatic castration-resistant prostate cancer.
Clin Cancer Res. 30:4115–4122. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Dariane C and Timsit MO: DNA-Damage-Repair
gene alterations in genitourinary malignancies. Eur Surg Res.
63:155–164. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Okuda Y, Kato T, Ishizuya Y, Hayashi T,
Yamamoto Y, Hatano K, Kawashima A, Murai J and Nonomura N: PARP
Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate
Cancer. Int J Urol. 32:1091–1101. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Virga A, Urbini M, Polano M, Petracci E,
Tedaldi G, Gurioli G, Marisi G, Angeli D, Ambrosini-Spaltro A, De
Luca G, et al: Mutational and low-coverage whole genome sequencing
identifies actionable DNA repair alterations in prostate cancer
plasma DNA. Sci Rep. 15:212962025. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Slootbeek PHJ, Tolmeijer SH, Mehra N and
Schalken JA: Therapeutic biomarkers in metastatic
castration-resistant prostate cancer: does the state matter? Crit
Rev Clin Lab Sci. 61:178–204. 2024. View Article : Google Scholar
|
|
151
|
Zhang X, Zhou F, Lu T, Zhang S, Wei X, Qiu
X, Xu L, Guo H and Zhuang J: Neoadjuvant darolutamide plus androgen
deprivation therapy for high-risk and locally advanced prostate
cancer: A multicenter, open-label, single-arm, phase II trial.
World J Urol. 43:582025. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Wong J, Tian Y, Patel MS, Avasthi K,
Hanson C, Larsen M, Ampaw E, Fadlullah MZH, Finklestein J, Tan AC,
et al: Plasma cell-free DNA methylation-based prognosis in
metastatic castrate-resistant prostate cancer. Res Sq [Preprint]
rs.3.rs-6331572. 2025.
|
|
153
|
Crumbaker M, Goldstein LD, Murray DH, Tao
J, Pathmanandavel S, Boulter N, Ratnayake L, Joshua AM, Kummerfeld
S and Emmett L: Circulating tumour DNA biomarkers associated with
outcomes in metastatic prostate cancer treated with
Lutetium-177-PSMA-617. Eur Urol Open Sci. 57:30–36. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Fei X, Du X, Gong Y, Liu J, Fan L, Wang J,
Wang Y, Zhu Y, Pan J, Dong B and Xue W: Early plasma circulating
tumor DNA as a potential biomarker of disease recurrence in
non-metastatic prostate cancer. Cancer Res Treat. 55:969–977. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Earland N, Chen K, Semenkovich NP, Chauhan
PS, Zevallos JP and Chaudhuri AA: Emerging roles of circulating
tumor DNA for increased precision and personalization in radiation
oncology. Semin Radiat Oncol. 33:262–278. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Lianidou E: Detection and relevance of
epigenetic markers on ctDNA: Recent advances and future outlook.
Mol Oncol. 15:1683–1700. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Huang YX, Wang HY, Zhang YH, Lin YF, Qiao
XQ and Hu LH: Bibliometric analysis of exosomes in the biomarker
research field. Se Pu. 43:498–507. 2025.PubMed/NCBI
|
|
158
|
Aseervatham J: Dynamic role of exosome
microRNAs in cancer cell signaling and their emerging role as
noninvasive biomarkers. Biology (Basel). 12:7102023.PubMed/NCBI
|
|
159
|
Trujillo B, Wu A, Wetterskog D and Attard
G: Blood-based liquid biopsies for prostate cancer: clinical
opportunities and challenges. Br J Cancer. 127:1394–1402. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Pudova E, Kobelyatskaya A, Katunina I,
Snezhkina A, Nyushko K, Fedorova M, Pavlov V, Bulavkina E, Dalina
A, Tkachev S, et al: Docetaxel resistance in castration-resistant
prostate cancer: Transcriptomic determinants and the effect of
inhibiting Wnt/β-catenin signaling by XAV939. Int J Mol Sci.
23:128372022. View Article : Google Scholar
|
|
161
|
Chen Z, Fu S, Shan Y, He Z, Gu J, Wu H,
Lin J, Huang Y, Wang H, Lu Y and Ding M: Circ_0001047 inhibits
prostate cancer progression and enhances abiraterone sensitivity
via miR-122-5p/FKBP5/PHLPPl/AKT axis in vitro. Discov Oncol.
15:5692024. View Article : Google Scholar
|
|
162
|
Song X, Li T, Zhou W, Feng C, Zhou Z, Chen
Y, Li D, Chen L, Zhao J, Zhang Y and Han B: CAF-derived exosomal
miR-196b-5p after androgen deprivation therapy promotes
epithelial-mesenchymal transition in prostate cancer cells through
HOXC8/NF-KB signaling pathway. Biol Direct. 20:802025. View Article : Google Scholar
|
|
163
|
Pecoraro G, Leone I, Nuzzo S, Negueruela
S, Smaldone G and Buono L: Co-modulation of a circular form of
PCDH11Y during neuroendocrine differentiation of prostate cancer.
Front Oncol. 15:15024052025. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Julio MK: Elevating prostate cancer
diagnostics through extracellular vesicle miRNAs. Gene. 1496622025.
View Article : Google Scholar
|
|
165
|
Qin X, Niu R, Tan Y, Huang Y, Ren W, Zhou
W, Wu H, Zhang J, Xu M, Zhou X, et al: Exosomal PSM-E inhibits
macrophage M2 polarization to suppress prostate cancer metastasis
through the RACK1 signaling axis. Biomark Res. 12:1382024.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zhang J, Chen B, Gan C, Sun H, Zhang J and
Feng L: A comprehensive review of small interfering RNAs (siRNAs):
Mechanism, therapeutic targets, and delivery strategies for cancer
therapy. Int J Nanomedicine. 18:7605–7635. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Kren BT, Henzler CM, Ahmed K and Trembley
JH: Impact of protein kinase CK2 downregulation and inhibition on
oncomir clusters 17 ~ 92 and 106b ~ 25 in prostate, breast, and
head and neck cancers. Mol Med. 30:1752024. View Article : Google Scholar
|
|
168
|
Shukla KK, Choudhary GR, Sankanagoudar S,
Misra S, Vishnoi JR, Pareek P, Pilla KK, Pandey SN and Sharma P:
Deregulation of miR-10b and miR-21 correlate with cancer stem cells
expansion through the apoptotic pathway in prostate cancer. Asian
Pac J Cancer Prev. 24:2105–2119. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Qiu J, Wu J, Zhou N, Lai C, Huang X, Liu
C, Yuan X and Xu K: An EcDNA gene-based risk model and functional
verification of a key ec-lncRNA AC016394.2 for prostate cancer.
Cancer Cell Int. 25:2402025. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Gupta P, Dutta S, Kumar P, Kaushik M,
Ashique S and Bhowmick M: Targeted management: Unlocking the
crucial role of PROTACs in cancer treatment. Curr Drug Discov
Technol. Feb 26–2025.Epub ahead of print. View Article : Google Scholar
|
|
171
|
Miao G, Shang Z and Wang X, Zhang J, Xu M,
He P, Zhong Q, Zhao X, Tan G and Wang X: Concurrent inhibition of
tumor growth and metastasis by a lipidated nanophotosensitizer
tracing and disabling tumor extracellular vesicles. Nat Cancer.
6:1438–1457. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Wang C, Feng Y, Rong X, Yan J, Lv B, Jiang
H, Duan L and Jiang J: Mesenchymal stromal cell exosomes for drug
delivery of prostate cancer treatments: A review. Stem Cell Res
Ther. 16:182025. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Bellomo G, Marcocci F, Bianchini D,
Mezzenga E, D'Errico V, Menghi E, Zannoli R and Sarnelli A: MR
spectroscopy in prostate cancer: New algorithms to optimize
metabolite quantification. PLoS One. 11:e01657302016. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Gungoren M, Koyuncu I, Kilinc E and Baysal
Z: Docetaxel-Loaded, Dipeptide-Functionalized
Y-Fe(2)O(3) magnetic nanoparticles: Synthesis,
characterization, and targeting to prostate cancer. Chem Biodivers.
22:e2024032452025. View Article : Google Scholar
|
|
175
|
Galey L, Olanrewaju A, Nabi H, Paquette
JS, Pouliot F and Audet-Walsh E: PSA, an outdated biomarker for
prostate cancer: In search of a more specific biomarker, citrate
takes the spotlight. J Steroid Biochem Mol Biol. 243:1065882024.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Jupin M, van Heijster FHA and Heerschap A:
Metabolite interactions in prostatic fluid mimics assessed by (1)H
NMR. MAGMA. 35:683–694. 2022. View Article : Google Scholar
|
|
177
|
Ma T, Xie W, Xu Z, Gao W, Zhou J, Wang Y
and Chan FL: Estrogen-related receptor alpha (ERRalpha) controls
the sternness and cellular energetics of prostate cancer cells via
its direct regulation of citrate metabolism and zinc
transportation. Cell Death Dis. 16:1542025. View Article : Google Scholar
|
|
178
|
Feng D, Zhang J, Niu H, Zheng X, Jia M, Lu
Q, Wang J, Guo W, Sun Q, Yuan H and Lou H: Spermidine inactivates
proteasome activity and enhances ferroptosis in prostate cancer.
Acta Pharm Sin B. 15:2095–2113. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Li QZ, Zuo ZW, Zhou ZR and Ji Y: Poly
amine homeostasis-based strategies for cancer: The role of
combination regimens. Eur J Pharmacol. 910:1744562021. View Article : Google Scholar
|
|
180
|
Tamura R, Chen J, De Jaeger M, Morris JF,
Scott DA, Vangheluwe P and Looger LL: Genetically encoded
fluorescent sensors for visualizing polyamine levels uptake, and
distribution. bioRxiv [Preprint]. 2024.08.21.609037. 2024.
|
|
181
|
Hunt RL, Oh J, Jain A, Kuo TH, Berardi D,
Jian W, Song D, Wu Q, Goodman AL, Palm NW, et al: Discovery of a
widespread polyamine-low-molecular-weight thiol hybrid pathway in
clostridioides difficile. ACS Infect Dis. 11:2246–2264. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng
Y, Zhang C, Liu D, Zheng M and Gao J: Mitochondrial dysfunction:
Mechanisms and advances in therapy. Signal Transduct Target Ther.
9:1242024. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Kumar R, Jonnatan S, Sanin DE, Vakkala V,
Kadam A, Kumar S, Dalrymple SL, Zhao L, Foley J, Holbert CE, et al:
Androgen receptor drives polyamine synthesis creating a
vulnerability for prostate cancer. medRxiv [Preprint].
2024.12.12.24318845. 2024.PubMed/NCBI
|
|
184
|
Danilova EY, Maslova AO, Stavrianidi AN,
Nosyrev AE, Maltseva LD and Morozova OL: CKD urine metabolomics:
Modern concepts and approaches. Pathophysiology. 30:443–466. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Zhu D, Dai J, Jia J, Kanagaraj T,
Rajalakshmi K, Muthusamy S, Geng L and Yuan G: Biogenic synthesis
of N-doped carbon dots from S. cumini seeds for prostate cancer
biomarker citrate detection, its live cancer cell imaging.
Spectrochim Acta A Mol Biomol Spectrosc. 329:1255682025. View Article : Google Scholar
|
|
186
|
Jimenez Gutierrez GE, Borbolla Jimenez FV,
Munoz LG, Tapia Guerrero YS, Murillo Melo NM, Cristobal-Luna JM,
Leyva Garcia N, Cordero-Martinez J and Magana JJ: The molecular
role of polyamines in age-related diseases: An update. Int J Mol
Sci. 24:164692023. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Lista S, Gonzalez-Dominguez R, Lopez-Ortiz
S, Gonzalez-Dominguez A, Menendez H, Martin-Hernandez J, Lucia A,
Emanuele E, Centonze D, Imbimbo BP, et al: Integrative metabolomics
science in Alzheimer's disease: Relevance and future perspectives.
Ageing Res Rev. 89:1019872023. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Sena LA: Polyamine metabolism in prostate
cancer. Curr Opin Oncol. 37:223–232. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Hu P, Yuan M, Guo B, Lin J, Yan S, Huang
H, Chen JL, Wang S and Ma Y: Citric acid promotes immune function
by modulating the intestinal barrier. Int J Mol Sci. 25:12392024.
View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Wu WF, Song XY, Warner M, Imamov O,
Antonson P and Gustafsson JA: The role of estrogen receptor beta in
maintaining basal cells and modulating the immune environment in
the prostate. Proc Natl Acad Sci USA. 122:e25057971222025.
View Article : Google Scholar
|
|
191
|
Ramatlho P, Rugemalila MM, Tawe L, Pain D,
Choga OT, Ndlovu AK, Koobotse MO, Lal P, Rebbeck TR, Paganotti GM,
et al: The role of immunohistochemistry for AMACR/p504s and p63 in
distinguishing prostate cancer from benign prostate tissue samples
in botswana. Res Rep Urol. 17:1–10. 2025.PubMed/NCBI
|
|
192
|
Spieker AJ, Gordetsky JB, Maris AS, Dehan
LM, Denney JE, Arnold Egloff SA, Scarpato K, Barocas DA and
Giannico GA: PTEN expression and morphological patterns in
prostatic adenocarcinoma. Histopathology. 79:1061–1071. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Zhang HZ, Wang SY, Guo YN and Zhao M:
Isolated intraductal carcinoma of the prostate: A
clinicopathological and molecular analysis. Zhonghua Bing Li Xue Za
Zhi. 53:803–808. 2024.In Chinese. PubMed/NCBI
|
|
194
|
Martini C, Logan JM, Sorvina A,
Prabhakaran S, Ung BSY, Johnson IRD, Hickey SM, Brooks RD; kConFab
Consortium; Caruso MC, et al: Distinct patterns of biomarker
expression for atypical intraductal proliferations in prostate
cancer. Virchows Arch. 485:723–728. 2024. View Article : Google Scholar :
|
|
195
|
Akhoundova D, Fischer S, Triscott J,
Lehner M, Thienger P, Maletti S, Jacquet M, Lubis DSH, Bubendorf L,
Jochum W and Rubin MA: Rare histologic transformation of a CTNNB1
(β-catenin) mutated prostate cancer with aggressive clinical
course. Diagn Pathol. 19:832024. View Article : Google Scholar
|
|
196
|
Ayala Soriano C, Benitez Barzaga M, Chhina
A, Jain M and Nava VE: Hepatoid prostatic carcinoma with adrenal
metastasis and novel genetic alterations. Diagn Cytopathol.
50:E310–E314. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Ruschoff JH, Stratton S, Roberts E, Clark
S, Sebastiao N, Fankhauser CD, Eberli D, Moch H, Wild PJ and Rupp
NJ: A novel 5x multiplex immunohistochemical staining reveals PSMA
as a helpful marker in prostate cancer with low p504s expression.
Pathol Res Pract. 228:1536672021. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Zhou L, Xu J, Wang S, Yang X, Li C, Zhou
J, Zhang P, Xu H and Wang C: Papillary renal neoplasm with reverse
polarity: A clinicopathologic study of 7 cases. Int J Surg Pathol.
28:728–734. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Nolan E, Lindeman GJ and Visvader JE:
Deciphering breast cancer: From biology to the clinic. Cell.
186:1708–1728. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Chenlo M, Aliyev E, Rodrigues JS,
Vieiro-Balo P, Blanco Freire MN, Cameselle-Teijeiro JM and Alvarez
CV: Sequential Colocalization of ERa, PR, and AR hormone receptors
using confocal microscopy enables new insights into normal breast
and prostate tissue and cancers. Cancers (Basel). 12:35912020.
View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Comperat E, Renard-Penna R, Ondet V,
Cancel-Tassin G and Cussenot O: Diagnosis of prostate cancer in one
day: The benefits of cytology in tumour detection. Cytopathology.
32:211–216. 2021. View Article : Google Scholar
|
|
202
|
Bee J, Zhou X, Tipirneni Y, Chen S, Qi J,
Iczkowski KA, Dall'Era M and Marcu L: Rapid discrimination of
high-grade prostate cancer using label-free fluorescence lifetime
measurements. medRxiv [Preprint]. 2025.05.23.25328257. 2025.
|
|
203
|
Riddi VL, Harahap EU, Sitinjak D and
Nirmawati R: Ductal adenocarcinoma of the prostate presenting with
bladder invasion and bone metastasis: A case report. Cureus.
17:e860002025.PubMed/NCBI
|
|
204
|
Salvi M, Manini C, Lopez JI, Fenoglio D
and Molinari F: Deep learning approach for accurate prostate cancer
identification and stratification using combined immunostaining of
cytokeratin, p63, and racemase. Comput Med Imaging Graph.
109:1022882023. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Bolis M, Bossi D, Vallerga A, Ceserani V,
Cavalli M, Impellizzieri D, Di Rito L, Zoni E, Mosole S, Elia AR,
et al: Dynamic prostate cancer transcriptome analysis delineates
the trajectory to disease progression. Nat Commun. 12:70332021.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Conte MI, Fuentes-Trillo A and Dominguez
Conde C: Opportunities and tradeoffs in single-cell transcriptomic
technologies. Trends Genet. 40:83–93. 2024. View Article : Google Scholar
|
|
207
|
Zhou L, Zhang C, Zhang Y and Shi C:
Application of organoid models in prostate cancer research. Front
Oncol. 11:7364312021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Mharrach I, Aqerrout M, Tadlaoui KA,
Laraqui A, Ghazzaly AE and Ennaji MM: Methylation status of GSTP1
and APC promoter genes as potential biomarkers for early detection
and tumor aggressiveness in prostate cancer: Insights from a
Moroccan cohort. Mol Biol Rep. 52:7112025. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Aloke C, Onisuru OO and Achilonu I:
Glutathione S-transferase: A versatile and dynamic enzyme. Biochem
Biophys Res Commun. 734:1507742024. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Gupta H, Inoue H, Nakai Y, Nakayama M,
Jones T, Hicks JL, Kumar B, Gurel M, Nelson WG, De Marzo AM and
Yegnasubramanian S: Progressive spreading of DNA methylation in the
GSTP1 promoter CpG island across transitions from precursors to
invasive prostate cancer. Cancer Prev Res (Phila). 16:449–460.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Ji R, Zhang L, Xing Y, Zhu Y, Mao K, Wang
M, Xuan K, Yang Y, Lo R, Luo B and Lu Z: Clinical significance of
urine-based automated detection of GSTP1 methylation for the
diagnosis of suspected prostate cancer patients. Transl Androl
Urol. 14:1204–1213. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Cussenot O, Timms KM, Perrot E, Blanchet
P, Brureau L, Solimeno C, Fromont G, Comperat E and Cancel-Tassin
G: Tumour-based mutational profiles predict visceral metastasis
outcome and early death in prostate cancer patients. Eur Urol
Oncol. 7:597–604. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Turan G, Turan M, Basbinar Y and Ellidokuz
H: Prostate cancer in Turkiye: Trend analysis of incidence and
mortality rates. Semin Oncol. 52:1523912025. View Article : Google Scholar
|
|
214
|
Lam D, Clark S, Stirzaker C and Pidsley R:
Advances in prognostic methylation biomarkers for prostate cancer.
Cancers (Basel). 12:29932020. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Eismann L, von Walter P, Jung A, Chaloupka
M, Rodler S, Westhofen T, Buchner A, Stief CG, Stadler T and
Schlenker B: Methylation status of various gene loci in localized
prostate cancer: Novel biomarkers for diagnostics and biochemical
recurrence. Urol Oncol. 41:325 el–325 e8. 2023. View Article : Google Scholar
|
|
216
|
Deng Y, Cai B and Wang X: A fully
automated quantitative analysis method based on deep learning
algorithms for immunohistochemical staining expression intensities.
Intell Oncol. 1:256–264. 2025. View Article : Google Scholar
|
|
217
|
Friedemann M, Horn F, Gutewort K, Tautz L,
Jandeck C, Bechmann N, Sukocheva O, Wirth MP, Fuessel S and
Menschikowski M: Increased sensitivity of detection of RASSF1A and
GSTP1 DNA fragments in serum of prostate cancer patients:
Optimisation of diagnostics using OBBPA-ddPCR. Cancers (Basel).
13:44592021. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Tufail M: PTEN-mediated resistance in
cancer: From foundation to future therapies. Toxicol Rep.
14:1019872025. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Bucker L and Lehmann U: CDH1 (E-cadherin)
gene methylation in human breast cancer: Critical appraisal of a
long and twisted story. Cancers (Basel). 14:43772022. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Corso G, Magnoni F, Dal Molin M, Marino E,
Nicosia L, Pesapane F, Noonan DM and Albini A: Second-hit CDH1 gene
mechanisms in hereditary diffuse gastric and lobular breast cancer
syndrome: Frequency and impact on tumorigenesis. Hum Mol Genet.
34:1345–1352. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Zhang W, Zhang K, Ma Y, Song Y, Qi T,
Xiong G, Zhang Y, Kan C, Zhang J, Han F and Sun X: Secreted
frizzled-related proteins: A promising therapeutic target for
cancer therapy through Wnt signaling inhibition. Biomed
Pharmacother. 166:1153442023. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Fiu C, Tang H, Hu N and Fi T: Methylomics
and cancer: The current state of methylation profiling and marker
development for clinical care. Cancer Cell Int. 23:2422023.
View Article : Google Scholar
|
|
223
|
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang
Y, Tian X, Guan X, Cen X and Zhao Y: Tumor biomarkers for
diagnosis, prognosis and targeted therapy. Signal Transduct Target
Ther. 9:1322024. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Ibrahim J, Peeters M, Van Camp G and Op de
Beeck K: Methylation biomarkers for early cancer detection and
diagnosis: Current and future perspectives. Eur J Cancer.
178:91–113. 2023. View Article : Google Scholar
|
|
225
|
Bao Y, Wang X, Zeng B, Shi Y, Huang Y,
Huang Y, Shang S, Shan F and Ma F: Research progress of liquid
biopsy based on DNA methylation in tumor diagnosis and Treatment.
Biomolecules. 14:16342024. View Article : Google Scholar
|
|
226
|
Wan JCM, Sasieni P and Rosenfeld N:
Promises and pitfalls of multi-cancer early detection using liquid
biopsy tests. Nat Rev Clin Oncol. 22:566–580. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Fi X and Fi X, Wang F, Hou Y, Fiu Y, Mao
J, Zhang F and Fi X: Advancing Traditional Chinese medicine
research through network pharmacology: Strategies for target
identification, mechanism elucidation and innovative therapeutic
applications. Am J Chin Med. 53:2021–2042. 2025. View Article : Google Scholar
|
|
228
|
Maliye R, Babu S, Harris AE, Patke R,
Ntekim AI, Rutland CS, James V, Mongan NP, Madhusudan S, Jeyapalan
JN and Semenova MM: Evaluation of human papillomavirus as a risk
factor in prostate cancer pathogenesis. Discov Oncol. 16:13752025.
View Article : Google Scholar : PubMed/NCBI
|
